Hillsdale Investment Management Inc. Catalyst Pharmaceuticals, Inc. Transaction History
Hillsdale Investment Management Inc.
- $1.77 Billion
- Q1 2025
A detailed history of Hillsdale Investment Management Inc. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Hillsdale Investment Management Inc. holds 197,100 shares of CPRX stock, worth $4.05 Million. This represents 0.27% of its overall portfolio holdings.
Number of Shares
197,100
Previous 190,000
3.74%
Holding current value
$4.05 Million
Previous $3.97 Million
20.53%
% of portfolio
0.27%
Previous 0.22%
Shares
13 transactions
Others Institutions Holding CPRX
# of Institutions
386Shares Held
103MCall Options Held
0Put Options Held
277K-
Black Rock Inc. New York, NY18.7MShares$384 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$180 Million0.0% of portfolio
-
State Street Corp Boston, MA5.48MShares$112 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.25MShares$66.8 Million0.1% of portfolio
-
Morgan Stanley New York, NY3.18MShares$65.4 Million0.0% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.11B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...